Acetylcysteine for the Prevention of Renal Outcomes in Patients With Diabetes Mellitus Undergoing Coronary and Peripheral Vascular Angiography A Substudy of the Acetylcysteine for Contrast-Induced Nephropathy Trial

被引：26

作者：

Berwanger, Otavio ^{[1
]}

Cavalcanti, Alexandre Biasi ^{[1
]}

Sousa, Amanda M. G. ^{[1
]}

Buehler, Anna ^{[1
]}

Castello-Junior, Helio Jose ^{[2
]}

Cantarelli, Marcelo J. C. ^{[2
]}

Mangione, Jose Armando ^{[3
]}

Bergo, Ricardo R. ^{[4
]}

Sao Thiago, Luiz Eduardo K. ^{[5
]}

Nunes, Paulo M. S. ^{[6
]}

Marra da Motta, Paulo Antonio ^{[7
]}

Kodama, Alessandra ^{[1
]}

Victor, Elivane ^{[1
]}

Carvalho, Vitor Oliveira ^{[1
]}

Sousa, Jose Eduardo ^{[1
]}

机构：

[1] HCor, Res Inst, BR-04005000 Sao Paulo, Brazil

[2] Hosp Bandeirantes, Sao Paulo, Brazil

[3] Hosp Beneficencia Portuguesa, Sao Paulo, Brazil

[4] Hosp Santa Luzia, Pocos De Caldas, Brazil

[5] Inst Cardiol, Sao Jose, Brazil

[6] Hosp Terapia Intens, Teresina, Brazil

[7] Inst Coracao, Taguatinga, Brazil

来源：

CIRCULATION-CARDIOVASCULAR INTERVENTIONS | 2013年 / 6卷 / 02期

关键词：

acetylcysteine; contrast-induced acute kidney injury; diabetes mellitus; randomized controlled trial; N-ACETYLCYSTEINE; INTERVENTION; FAILURE; METAANALYSIS; NEPHROTOXICITY;

D O I：

10.1161/CIRCINTERVENTIONS.112.000149

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background-Diabetes mellitus represents an independent risk factor for contrast-induced acute kidney injury. We report the results of a prespecified substudy of patients with diabetes mellitus included in the Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT), the largest randomized study evaluating the effects of acetylcysteine for the prevention of contrast-induced acute kidney injury conducted to date. Methods and Results-From the 2308 patients included in the ACT, 1395 had diabetes mellitus and were considered for the present analysis. The study drugs (acetylcysteine 1200 mg or matching placebo) were administered orally twice daily for 2 doses before and 2 doses after the procedure. The allocation was concealed (central Web-based randomization). Participants, healthcare staff, data collectors, and outcome assessors were blinded. All analysis followed the intention-to-treat principle. The incidence of contrast-induced acute kidney injury (primary end point) was 13.8% in the acetylcysteine group and 14.7% in the control group (relative risk 0.93; 95% confidence interval, 0.69-1.26; P=0.64). A combined end point of death or need for dialysis at 30 days was also similar in both the groups (2.2% and 2.1%, respectively; hazard ratio, 1.07; 95% confidence interval, 0.52-2.19; P=0.86). Conclusions-In this subanalysis, acetylcysteine did not reduce the risk of contrast-induced acute kidney injury or other clinically relevant outcomes in patients with diabetes mellitus undergoing coronary and peripheral vascular angiography.

引用

页码：139 / +

页数：8

共 32 条

[1]

Azmus Alexandre D, 2005, J Invasive Cardiol, V17, P80

[2] Acetylcysteine in the prevention of contrast-induced nephropathy - A case study of the pitfalls in the evolution of evidence [J].

Bagshaw, SM ;

McAlister, FA ;

Manns, BJ ;

Ghali, WA .

ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (02) :161-166

[3] Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification [J].

Bartholomew, BA ;

Harjai, KJ ;

Dukkipati, S ;

Boura, JA ;

Yerkey, MW ;

Glazier, S ;

Grines, CL ;

O'Neill, WW .

AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (12) :1515-1519

[4] Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT) [J].

Berwanger, Otavio ;

Cavalcanti, Alexandre B. ;

Sousa, Amanda G. M. R. ;

Buehler, Anna M. ;

Kodama, Alessandra A. ;

Carballo, Mariana T. ;

Carvalho, Vitor O. ;

Amodeo, Celso ;

Lotaif, Leda D. ;

Sousa, Jose Eduardo ;

Victor, Elivane S. ;

Santucci, Eliana ;

Cardoso, Carlos E. S. ;

da Silva, Dalmo ;

Mendes, Adailton L. ;

Lobato, Jose ;

Prates, G. ;

Yokoyama, H. ;

Almeida, P. ;

Pessoa, C. ;

Martins, H. ;

Lopes, M. ;

Barros, M. ;

Reis, H. ;

Cordeiro, C. ;

Castello, H. ;

Cantarelli, M. ;

Ferreira, S. ;

Mattos, C. ;

Rati, M. ;

Medeiros, C. ;

Mangione, J. A. ;

Mauro, M. F. ;

Cristovao, S. A. ;

Carnieto, N. M. ;

Rocha, L. C. ;

Maksud, D. F. ;

Barbosa, C. ;

Costantini, C. ;

Tarbine, S. ;

Santos, M. ;

Ortiz, C. ;

Souza, A. ;

Mattos, C. ;

Duarte, L. ;

Marin Neto, J. ;

Figueiredo, G. ;

Lemos, D. ;

Braga, F. ;

Novaes, G. .

CIRCULATION, 2011, 124 (11) :1250-1259

[5]

Brar SS, 2012, LAT BREAK TRIAL 24 T

[6] N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity [J].

Briguori, C ;

Colombo, A ;

Airoldi, F ;

Violante, A ;

Castelli, A ;

Balestrieri, P ;

Elia, PP ;

Golia, B ;

Lepore, S ;

Riviezzo, G ;

Scarpato, P ;

Librera, M ;

Focaccio, A ;

Ricciardelli, B .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (04) :762-765

[7] Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity [J].

Briguori, C ;

Colombo, A ;

Violante, A ;

Balestrieri, P ;

Manganelli, F ;

Elia, PP ;

Golia, B ;

Lepore, S ;

Riviezzo, G ;

Scarpato, P ;

Focaccio, A ;

Librera, M ;

Bonizzoni, E ;

Ricciardelli, B .

EUROPEAN HEART JOURNAL, 2004, 25 (03) :206-211

[8]

Buyse M, 1999, STAT MED, V18, P3435, DOI 10.1002/(SICI)1097-0258(19991230)18:24<3435::AID-SIM365>3.0.CO

[9]

2-O

[10] Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy [J].

Costa, Eduardo ;

Reis, Helder ;

de Assis, Gabriela M. C. C. ;

Cardoso, Gracilene L. ;

Barbosa, Marcio M. ;

de Aguiar Filho, Francisco A. A. ;

Gama, Carlos A. V. ;

Silva, Marcelo Goes A. ;

Aguiar, Bruno M. ;

Ferreira, Marcelo G. ;

Feitosa, Gilson S. ;

Victor Filho, Edgard ;

Rocha, Emmanuel B. D. ;

Paiva, Maria S. M. O. ;

Czochra, Eliana R. ;

Oliveira, Ludmila A. R. R. ;

de Oliveira, Itamar R. ;

Pinheiro, Flavia ;

Dourado, Gilvan O. ;

Luna Filho, Antonio L. ;

Pacheco, Amilson ;

Nunes, Paulo M. S. ;

de Sa Filho, Alcino P. ;

Martins, Helman C. ;

Lopes, Marcelo A. C. ;

Barros, Marco A. V. ;

Mattos, Claudia ;

Neves, Miguel A. ;

Medeiros, Cesar Rocha ;

Duarte, Leonardo ;

Cramer, Helena ;

Santos, Braulio, Jr. ;

Tura, Bernardo R. ;

Rodrigues, Cyro V. ;

Terreiro, Luis A. O. ;

Alves, Monica A. ;

Soares, Jamil S. ;

da Cunha, Cristiane C. ;

da Silva, Antonio C. B. ;

Barcelos, Alexandre M. ;

Teixeira, Marco A. ;

Pinto, Joselena S. ;

Saad, Jamil A. ;

Mandil, Ari ;

Falcheto, Eduardo ;

Areas, Carlos Augusto F. ;

Dall'Orto, Frederico T. C. ;

Freitas, Ivan F. ;

Botelho, Roberto V. ;

Seabra, Miriam D. G. .

TRIALS, 2009, 10

← 1 2 3 4 →